Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06227026
Title Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY)
Acronym PRODIGY
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.